NEWS

Cepheid Receives IVDR CE Mark for Xpert GI Panel to Detect 11 Gastrointestinal Pathogens

Shots: Cepheid has received IVDR CE marking for the Xpert GI Panel, a multiplex PCR assay designed to detect 11 clinically relevant GI pathogens from a single stool sample using the 10-color multiplexing technology on GeneXpert Systems The assay simultaneously identifies bacterial, viral, & parasitic pathogens directly from stool specimens in Cary-Blair transport media, requiring…

May 13, 2026

Astellas Reports the Post Hoc Analysis from GATHER Trials on Izervay in Geographic Atrophy Secondary to AMD at ARVO’26

Shots: The GATHER1 & GATHER2 studies assessed Izervay (QM) vs sham in pts with GA secondary to AMD for 18 & 12mos., respectively, where in GATHER2, pts were later re-randomized to Izervay QM or Q2M for 24mos. In the driving-eligible pts (BCVA of ≥70 ETDRS letters; n=403), Izervay reduced the risk of losing driving eligibility…

May 13, 2026

IQVIA and Kexing Biopharm Strengthen Strategic Collaboration to Advance Global Biosimilar Development through AI-enabled Capabilities

Shots: IQVIA is expanding its collaboration with Kexing Biopharm to advance a global multi-product biosimilar development and commercialization program As part of the collaboration, IQVIA will provide end-to-end development, regulatory, analytics, and commercialization support to accelerate Kexing’s global biosimilar expansion while maintaining high quality and scientific standards The collaboration also integrates IQVIA’s AI-enabled clinical trial capabilities to streamline protocol design, site selection,…

May 13, 2026

AstraZeneca Presents the P-III (CALYPSO) Trial Data on Eneboparatide in Chronic Hypoparathyroidism (HypoPT) at ECE’26

Shots: Trial assessed eneboparatide (ENB; QD, SC) vs PBO for 24wks. in 202 adults with HypoPT on active vitamin D & oral Ca supplements; Pts then continued ENB (ENB/ENB) or switched from PBO to ENB (PBO/ENB) in a 28wk. OLE Trial met its composite 1EP, with 31.1% pts achieving normalized albumin-adjusted sCa levels & independence…

May 13, 2026

Isomorphic Labs Raises $2.1B in Series B Funding to Scale AI Drug Design Engine & Advance Pipeline

Shots: Isomorphic Labs has reported a $2.1B Series B financing round led by Thrive Capital, with participation from existing investors Alphabet & GV alongside new backers MGX, Temasek, CapitalG, & the UK Sovereign AI Fund The company plans to use the capital to further develop & deploy its AI-powered drug discovery platform, IsoDDE, accelerate internal…

May 13, 2026

Boehringer Ingelheim Inks ~$ 479.6M Deal with Immunitas Therapeutics for a Preclinical Antibody Program

Shots: BI has entered into a global licensing agreement with Immunitas for a preclinical antibody program being developed for chronic inflammatory & autoimmune diseases As per the deal, BI will obtain global rights to develop, manufacture, & commercialize the antibody program in exchange for an upfront payment, up to €407.5M (~$479.6M) in development, regulatory, &…

May 13, 2026

Rigel Signs ~$445M Licensing Pact with Arvinas and Pfizer for Veppanu

Shots: Rigel has entered into an exclusive, global license agreement with Arvinas & Pfizer to develop, manufacture & commercialize FDA-approved Veppanu (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer. As per the deal, Rigel will pay Arvinas & Pfizer $70M upfront, $15M in upon completion of transition activities, & ~$320M in milestones plus tiered royalties…

May 12, 2026

Tolion Health AI Launches AI-Powered Tolion Brain Coach App for Brain Health, Longevity, and Prevention of Alzheimer’s Disease

Shots: Tolion Health AI has launched Tolion Brain Coach, a new App within its Brain Health Platform designed to deliver personalized, preventive, & predictive insights for cognitive health using AI-driven analytics & wearable-device data Platform leverages Tolion’s Knowledge Engine & Brain Score to generate tailored recommendations aimed at strengthening cognitive resilience & reducing neurodegenerative disease…

May 12, 2026

Novo Nordisk Reports New STEP UP Trial Analyses on Wegovy 7.2mg for Weight Loss

Shots: Novo Nordisk has reported sub-analysis from the STEP UP trial assessing Wegovy (7.2mg, QW) vs Wegovy (2.4mg) & PBO alongside lifestyle intervention for 72wks. in >1,400 obese adults without diabetes (BMI ≥30kg/m²) Wegovy 7.2mg achieved 20.7% average weight loss vs 17.5% (2.4mg) & 2.4% (PBO); among early responders (≥15% loss by wk. 24), 26.9%…

May 12, 2026

Exero Medical Reports the Trial Data on xBar Monitoring System for Early Detection of Colorectal Surgery Complications

Shots: Exero Medical has reported clinical trial data assessing xBar monitoring system to detect post-operative anastomotic leaks in colorectal resection surgery pts (n=222) Study showed that the xBar system detected post-operative anastomotic leaks in colorectal resection pts earlier than standard clinical practice, achieving 100% sensitivity & 88% specificity by post-operative day 3 & identifying leaks…

May 12, 2026

Cepheid Receives IVDR CE Mark for Xpert GI Panel to Detect 11 Gastrointestinal Pathogens

Astellas Reports the Post Hoc Analysis from GATHER Trials on Izervay in Geographic Atrophy Secondary to AMD at ARVO’26

IQVIA and Kexing Biopharm Strengthen Strategic Collaboration to Advance Global Biosimilar Development through AI-enabled Capabilities

AstraZeneca Presents the P-III (CALYPSO) Trial Data on Eneboparatide in Chronic Hypoparathyroidism (HypoPT) at ECE’26

Isomorphic Labs Raises $2.1B in Series B Funding to Scale AI Drug Design Engine & Advance Pipeline

Boehringer Ingelheim Inks ~$ 479.6M Deal with Immunitas Therapeutics for a Preclinical Antibody Program

Rigel Signs ~$445M Licensing Pact with Arvinas and Pfizer for Veppanu

Tolion Health AI Launches AI-Powered Tolion Brain Coach App for Brain Health, Longevity, and Prevention of Alzheimer’s Disease

Novo Nordisk Reports New STEP UP Trial Analyses on Wegovy 7.2mg for Weight Loss

Exero Medical Reports the Trial Data on xBar Monitoring System for Early Detection of Colorectal Surgery Complications

Contact US

FOLLOW US